https://ntp.niehs.nih.gov/go/5616

TDMS Study 89029-12 Pathology Tables

NTP Experiment-Test: 89029-12  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:08
                                          MAGNETIC FIELDS + DMBA INITIATION PROMOTION
                       20MG(5MGX4)DMBA V 50 HZ/1G 20MG(5MGX4)DMBA V 50 HZ/5G 20MG(5MGX4)DMBA V 60 HZ/1G 20MG(5MGX4)DMBA
       Facility:  Battelle Northwest
       Chemical CAS #:  EMF + DMBA
       Lock Date:  10/14/97
       Cage Range:  All
       Reasons For Removal:    All
       Removal Date Range:     All
       Treatment Groups:       Include 001    20 DMBA CONTROL
                               Include 003    50 HZ/1G 20 DMBA
                               Include 005    50 HZ/5G 20 DMBA
                               Include 004    60 HZ/1G 20 DMBA
a  Number of animals examined microscopically at site and number of animals with lesion
                                                              Page   1
NTP Experiment-Test: 89029-12  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:08  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL       20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY                                                                                                                 
  Animals Initially in Study                         100          100          100          100                                     
  Early Deaths                                                                                                                      
    Natural Death                                      3            6            4            2                                     
    Moribund Sacrifice                                 3            7            4            3                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                93           86           92           94                                     
    Natural Death                                                   1                         1                                     
    Moribund Sacrifice                                 1                                                                            
  Animals Examined Microscopically                   100          100          100          100                                     
____________________________________________________________________________________________________________________________________
 ALIMENTARY SYSTEM                                                                                                                  
   Liver                                              (100)        (100)        (100)        (100)                                  
      Carcinoma, Metastatic, Mammary Gland             1 (1%)                                 1 (1%)                               
____________________________________________________________________________________________________________________________________
 CARDIOVASCULAR SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 ENDOCRINE SYSTEM                                                                                                                   
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENERAL BODY SYSTEM                                                                                                                
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENITAL SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 HEMATOPOIETIC SYSTEM                                                                                                               
   Lymph Node                                         (2)          (2)                                                              
____________________________________________________________________________________________________________________________________
                                                             Page   2                                                               
NTP Experiment-Test: 89029-12  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98 
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:08  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL       20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
 INTEGUMENTARY SYSTEM                                                                                                               
   Mammary Gland                                      (100)        (100)        (100)        (100)                                  
      Adenoma                                          2 (2%)       1 (1%)                    1 (1%)                                
      Carcinoma                                        4 (4%)       8 (8%)       9 (9%)       5 (5%)                                
      Carcinoma, Multiple                             88 (88%)     78 (78%)     87 (87%)     91 (91%)                               
      Carcinoma, Metastatic, Zymbal's Gland                                                   1 (1%)                                
      Fibroadenoma                                     3 (3%)       2 (2%)       1 (1%)       1 (1%)                                
____________________________________________________________________________________________________________________________________
 MUSCULOSKELETAL SYSTEM                                                                                                             
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 NERVOUS SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 RESPIRATORY SYSTEM                                                                                                                 
   Lung                                               (100)        (100)        (100)        (100)                                  
      Carcinoma, Metastatic, Mammary Gland             1 (1%)       1 (1%)       1 (1%)                                        
____________________________________________________________________________________________________________________________________
 SPECIAL SENSES SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 URINARY SYSTEM                                                                                                                     
   Kidney                                             (100)        (100)        (100)        (100)                                  
____________________________________________________________________________________________________________________________________
 SYSTEMIC LESIONS                                                                                                                   
   Multiple Organs                                   *(100)       *(100)       *(100)       *(100)                                  
      Leukemia Mononuclear                            15 (15%)     16 (16%)     10 (10%)     12 (12%)                               
____________________________________________________________________________________________________________________________________
     *   Number of animals with any tissue examined microscopically                                                                 
                                                             Page   3                                                               
NTP Experiment-Test: 89029-12  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: SUBCHRON 90-DAY                    MAGNETIC FIELDS + DMBA INITIATION PROMOTION                        Date: 01/30/98  
Route: MAGNETIC FIELDS                                                                                            Time: 16:02:08  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                20 DMBA      50 HZ/1G     50 HZ/5G     60 HZ/1G                                  
                                                   CONTROL       20 DMBA      20 DMBA      20 DMBA                                  
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY                                                                                                                       
   Total Animals with Primary Neoplasms (b)            94          92          96          96                                       
     Total Primary Neoplasms                          120         109         114         115                                       
   Total Animals with Benign Neoplasms                  5           3           1           2                                       
     Total Benign Neoplasms                             5           3           1           2                                       
   Total Animals with Malignant Neoplasms              93          92          96          96                                       
     Total Malignant Neoplasms                        115         106         113         113                                       
   Total Animals with Metastatic Neoplasms              1           1           1           2                                       
     Total Metastatic Neoplasm                          2           1           1           2                                       
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                             Page   4            
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------